Controversies exist with regard to the optimal management of atrial fibrillation (AF). Restoration and maintenance of sinus rhythm is a desirable goal in AF patients because the prevention of recurrences may improve cardiac function, relieve symptoms and should reduce the likelihood of adverse events. Pharmacological therapy for AF has been disappointing with unacceptable rates of AF recurrence and other proarrhythmic sequelae. Recent studies suggested that potential benefit of sinus-rhythm maintenance with respect to mortality may have been neutralized by harmful effects of currently available antiarrhythmic therapies. Because of the inefficacy and dangers with nonablative therapies currently available for maintaining sinus rhythm, alternative treatments are certainly desirable. Curative treatment of atrial fibrillation with catheter ablation is now a legitimate option for a large number of patients.
Introduction
Atrial fibrillation (AF) is the most common cardiac rhythm disturbance seen in clinical practice [Kannel et al. 1982] accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances. The estimated prevalence of AF is 0.4-1% in the general population, increasing with age [Go et al. 2001; Feinberg et al. 1995] , and it is associated with an increased long-term risk of stroke, heart failure, and all-cause mortality, especially in women [Kannel and Benjamin, 2008; Stewart et al. 2002] . Atrial fibrillation may occur both in isolation and in association with structural heart disease. However, although a great proportion of patients with AF have no detectable heart disease, AF substantially contributes to cardiac morbidity and mortality also in this subset of patients.
Although recent advances in pharmacological and nonpharmacological therapy, AF management remains problematic and controversial and has been the subject of intense investigation over the past two decades. The long-term management of this arrhythmia includes two generally acceptable strategies: (1) one strategy attempts restoration and/or maintenance of sinus rhythm with pharmacological and nonpharmacological antiarrhythmic approaches; (2) in the second approach the ventricular rate is controlled with no commitment to restore or maintain sinus rhythm. Regardless of whether the rate-or rhythm-control strategy is pursued, attention must also be directed to antithrombotic therapy for prevention of thromboembolism.
Approach to the patient with AF: heart rate control or rhythm control? The initial and subsequent management of symptomatic AF may differ from one patient to another. A few randomized trials comparing outcomes of rhythm-versus rate-control strategies have been published. In particular, the AF Follow-up Investigation of Rhythm Management (AFFIRM), Rate Control Versus Electrical Cardioversion for AF (RACE), and Strategies for Treatment of AF (STAF) trials compared a strategy of rate control and a rhythm control approach using antiarrhythmic drugs (AAD) [Hagens et al. 2004; Carlsson et al. 2003; Wyse et al. 2002] . The analysis of these trials demonstrated no difference in mortality or stroke rate between patients assigned to one strategy or the other. These results are generally interpreted as showing that either rate control or rhythm control is a suitable strategy in a patient with atrial fibrillation. Additionally these findings are consistent with the results of the Atrial Fibrillation and Congestive Heart Failure trial [Roy et al. 2008 ] that recently showed that a routine strategy of rhythm control in patients with atrial fibrillation and congestive heart failure does not reduce the rate of death from cardiovascular causes as compared with a rate-control strategy.
However, it would be incorrect to extrapolate that it is not worthwhile to attempt to restore sinus rhythm for a multitude of reasons. First, these trials were not comparisons of sinus rhythm and AF. Indeed, in one study (RACE), only 39% of patients in the rhythm-control group had sinus rhythm at the end of follow-up. Consequently, a significant limitation of these studies is that the rhythm-control strategy with AAD was not efficacious. Many patients in the rate-control arm were spontaneously in sinus rhythm by the end of the study periods, from 10% in STAF and RACE to 35% in AFFIRM. Therefore the results of these studies may reflect the ineffectiveness of the rhythm control methods used. When the data from these trials are analyzed according to the patient's actual rhythm, the benefit of sinus rhythm over AF becomes apparent [Corley et al. 2004 ]. This benefit might have been reduced by the use of AAD, which increased the risk of death. The reduction in mortality with sinus rhythm has also been demonstrated in virtually every study that has monitored this end point.
Another methodological concern is that in the rhythm control group, continuous anticoagulation was encouraged but could be stopped at the physician's discretion whereas in the ratecontrol group continuous anticoagulation was mandated by the protocol. Importantly, most strokes were diagnosed after discontinuation of anticoagulation or at subtherapeutic intensity (international normalized ratio below 2.0). In addition, while recurrent AF was detected in only about one-third of those in the rhythmcontrol groups who developed stroke, at the time of ischemic stroke patients in the rate-control groups typically had AF. We strongly believe that adequate anticoagulation with warfarin would have substantially lowered the risk of stroke in the rhythm-control groups.
Another important issue is that in the rhythmcontrol group of the AFFIRM trial the proportion of patients using beta-blocking drugs at any time during the study was significantly smaller than that in the rate-control group (49.6% versus 68.1%). This difference is essential, because there is accumulating evidence that beta-blocker treatment improves the prognosis in patients with coexistent structural heart disease that were largely represented in these studies.
Finally, it is also important to acknowledge that the patients enrolled in these trials do not represent the full spectrum of AF patients. In particular, patients in whom atrial fibrillation caused severe symptoms that would most benefit from sinus rhythm were largely excluded from the AFFIRM trial. Clearly, in such patients the goal is still the maintenance of sinus rhythm, and the quest for better drugs and techniques to achieve this goal will, and should, continue.
Restoration and maintenance of sinus rhythm: treating AF with medical therapy Antiarrhythmic drug therapy is the first line of treatment for patients with paroxysmal and persistent AF based on current guidelines. However, the currently available antiarrhythmic agents have poor efficacy and are associated with a plethora of significant side effects, both cardiac and noncardiac. Consequently, the limited efficacy and proarrhythmic risks of AAD for atrial fibrillation have led to the development of nonpharmacologic therapeutic approaches.
Patients who do not receive AAD have a 1-year AF recurrence rate of about 75%. With antiarrhythmic drugs, sinus rhythm may be maintained in 50-65% of cases. The choice of antiarrhythmic agent should be guided by the presence or absence of structural heart disease, tolerability, ease of administration and side-effect profile. The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.
Several drugs including amiodarone, propafenone, flecainide and sotalol have been shown to be effective in the prevention of AF recurrences. These agents often do not totally abolish the arrhythmia, but they increase the length of the arrhythmia-free interval. The best available agent for rhythm control is amiodarone [Singh et al. 2005; Roy et al. 2000 ]. In the Canadian Trial of Atrial Fibrillation, amiodarone was compared with propafenone and sotalol for suppression of AF. Amiodarone was associated with a 35% rate of AF recurrence at 16 months compared with a 63% rate of recurrence with the other study drugs. Currently amiodarone is approved by the Food and Drug Administration for the treatment of ventricular arrhythmias but not for the management of atrial fibrillation. Even so, it is widely prescribed for this indication. In addition it is an excellent choice for use in patients with structural heart disease or congestive heart failure as most other antiarrhythmic medications are contraindicated in heart failure patients. Amiodarone is less proarrhythmic than other agents but can adversely affect lungs, thyroid and other organs, [Zimetbaum, 2007] . After 5 years, 30% of patients on amiodarone will discontinue therapy because of side effects [Chun et al. 1995] . Dronedarone, a new derivative of amiodarone, lacks the iodine component that is largely responsible for the latter's multiple organ toxicities. Recent randomized trials [Hohnloser et al. 2009; Singh et al. 2007 ] showed that dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia. In the ATHENA trial [Hohnloser et al. 2009 ] which randomized 4628 moderateto high-risk AF patients, dronedarone use resulted in a significant reduction (hazard ratio 0.76) in the primary endpoint of cardiovascular hospitalizations or death with rates of clinically important adverse events similar to those seen with placebo. However, the efficacy of dronedarone to suppress AF doesn't seem quite as strong as that of amiodarone. Moreover, the potential adverse effects of dronedarone on patients hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction [Kober et al. 2008 ] remains an unresolved concern.
Discontinuation rates for AAD are consistently high in most trials. The careful use of these medications as demonstrated in AFFIRM can minimize this risk but does not eliminate it entirely [AFFIRM Investigators 2003] . A careful history taking and physical examination are mandatory in order to evaluate any potentially negative effect that the therapy for the arrhythmia may have on the underlying heart disease. However in some patients not only is efficacy lower than desired, but prediction of antiarrhythmic versus arrhythmogenic effects of AAD in a particular case is nearly impossible.
First episode of atrial fibrillation
An attempt to restore sinus rhythm is a reasonable approach to a first episode of atrial fibrillation. After this episode, the arrhythmia-free period is unpredictable, and it may not be necessary to prescribe either long-term antiarrhythmic therapy or anticoagulation for all patients after the first documented episode. Cardioversion might even be performed initially without the use of antiarrhythmic drugs. This approach may result in the maintenance of sinus rhythm for a year or more in about 25% of patients. If arrhythmia recurs and if symptoms persist despite AAD, repeated cardioversion with the addition of antiarrhythmic drugs should be considered.
Rate control during atrial fibrillation
Chronic AF and uncontrolled ventricular rate can both result in LV dysfunction or contribute to its progression. Drugs that prolong the AV node refractory period are generally effective for rate control. The efficacy of pharmacological interventions designed to achieve rate control in patients with AF has been about 80% in clinical trials [Weerasooriya et al. 2003 ]. However, adverse effects such as bradycardia and heart block may occur, especially in the elderly. Nonpharmacological therapy should be considered when pharmacological measures fail. Radiofrequency ablation of the atrioventricular junction with pacemaker implantation can improve symptoms and LV function in some patients [Wood et al. 2000 ], but the potential for decrease in mortality needs to be proved.
Which approach to rate control Randomized studies suggest combining betablockers or calcium-channel blockers with digoxin to achieve better rate control at rest and during exercise [Tamariz and Bass, 2004; Farshi et al. 1999 ]. Beta-blocking agents are probably the drugs of choice in patients with systolic dysfunction and/or coronary artery disease.
The aims of pharmacologic control of the heart rate in patients with atrial fibrillation are to minimize symptoms and prevent excessive tachycardia. However, the optimal level of heart rate for patients with atrial fibrillation remains unclear. Rate-control approach in RACE and AFFIRM trial was a resting heart rate 580 or 5100 beats per minute, respectively. However, a substudy of the AFFIRM [Olshansky et al. 2004] showed that the rate-control approach was successfully achieved in two-thirds of the patients. Additionally, to obtain adequate rate control, atrioventricular node ablation and pacemaker implantation was performed 5.3% patients, and an additional 17.3% patients had a pacemaker implanted for symptomatic bradycardia. Unfortunately, these studies give no data on the influence of the level of rate control on mortality and morbidity. Therefore, as it still remains unknown whether strict rate control is associated with an improved prognosis, a long-term prospective, randomized trial would be useful.
Nonpharmacologic therapeutic approaches to rhythm control For many years, a pharmacological approach was the only therapeutic modality available for managing AF. Because antiarrhythmic therapy has several limitations, including unacceptable rates of AF recurrence and other proarrhythmic sequelae, nonpharmacological approaches have become increasingly important therapeutic alternatives. Recent observations on the mechanisms of atrial fibrillation have resulted in the development of different nonpharmacological treatment directed to eliminate the triggers and to modify the electrophysiological substrate for the prevention and treatment of the disorder.
Surgical maze approach
With the introduction by Cox et al. [1991] of a surgical technique to create conduction barriers at the critical area in order to reduce the critical mass within both atria, the possibility of a surgical cure of AF was raised. Since its introduction, modifications of the Cox/MAZE procedure have attempted to preserve efficacy but reduce complexity thereby improving adoptability. There are now different surgical ablative techniques that can effectively modify the atrial substrate [Kim et al. 2001; Cox et al. 1995; Kosakai et al. 1994 ]. By making a series of atrial incisions and cryolesions this procedure results in the interruption of the multiple re-entry circuits necessary for the propagation of AF ( Figure 1D ). However, the original intention of Cox was to place the surgical incisions so that the SA node impulse could propagate throughout both atria, allowing most of the atrial myocardium to be activated and preserving atrial transport function in most patients. These procedures require thoracotomy and cardiopulmonary bypass, however, and they are associated with morbidity as well as the risk of serious complications. Currently, most surgical MAZE procedures are performed in conjunction with other cardiac operations (concomitant MAZE) particularly mitral-valve surgery [Izumoto et al. 2000] . Success rates of around 95% over 15 years of follow-up have been reported in patients undergoing mitral valve surgery [Gillinov and McCarthy, 2004; Damiano et al. 2003 ]. Other studies suggest success rates of around 70%. Recent advances in surgical procedures using alternate energy sources such as thoracoscopic and catheter-based epicardial techniques may become more acceptable alternatives for a wider population of patients with atrial fibrillation.
Catheter ablation
In the last 10 years, left atrial catheter ablation (CA) has been proposed as a definitive cure across a broad spectrum of patients, from patients with paroxysmal AF to those with long-lasting persistent AF. Continuing advances in this field are leading to more patients being offered this treatment option. A number of different ablation strategies have been used including pulmonary vein isolation, targeting of fractionated electrograms, autonomic ganglionated plexi ablation, compartmentalizing the atria with linear lesions and various combinations and modifications of these lesion sets ( Figure 1A-1C ). The optimal ablation strategy for both paroxysmal and longlasting persistent atrial fibrillation is unknown.
Randomized, controlled trials (Table 1) comparing RF ablation with antiarrhythmic medications in the treatment of AF have been published [Forleo et al. 2009; Jais et al. 2008; Pappone et al. 2006; Stabile et al. 2006; Oral et al. 2006; Wazni et al. 2005] . Most studies included patients with paroxysmal or persistent AF who had failed at least one or two antiarrhythmic medications or who were intolerant of antiarrhythmic medications. These studies demonstrated the superiority of catheter ablation over antiarrhythmic drugs in patients with AF with regard to maintenance of sinus rhythm and improvement in symptoms, exercise capacity, and quality of life. The current guidelines recommend catheter ablation in this setting. However, one trial [Oral et al. 2006 ] assessed the efficacy of ablation in patients with permanent AF whereas another study randomized patients as first-line therapy [Wazni et al. 2005 ] suggesting that catheter ablation can be considered early in the management of patients. Recently, a systematic review showed that in patients with paroxysmal and persistent AF and structurally normal hearts, ablation therapy results in a 65% reduction in the risk of AF recurrence compared with standard antiarrhythmic therapy [Nair et al. 2008] .
Of note, a recent study that compared the cost of ablation as first-line treatment of symptomatic AF versus that of antiarrhythmic drug therapy, demonstrated that CA was cost-neutral 2 years after the initial procedure. Additionally, accumulating evidence from clinical studies have documented long-term improvement in quality-of-life, functional capacity and left ventricular function in patients with impaired systolic function who undergo CA of AF [Khan et al. 2008; Oral et al. 2006; Tondo et al. 2006; Chen et al. 2004; Hsu et al. 2004] . A major advantage of CA is that patients with low ejection fraction are at an increased risk of AAD adverse effects; however, the disadvantages of CA include a higher procedural risk in this subset of patients.
Nevertheless, many aspects of the therapy are still controversial, from ablation techniques to procedural endpoints, patient management, definition of success and long-term results. The definition of a successful intervention for the management of AF remains a challenge. It remains uncertain whether apparent cures represent elimination of AF or transformation into an asymptomatic form of AF unrecognized by the patient or the physician. The distinction has great significance from the point of view of preventing thromboembolic episodes in patients with risk factors for stroke associated with AF.
Targets for catheter ablation
It is likely that in humans AF is caused by different mechanisms. Recent observations have focused attention on the pulmonary veins (PV) as a source of ectopic activity determining AF [Chen and Chen, 2006; Haissaguerre et al. 1998 ]. However a predisposing atrial substrate of sufficient mass capable of maintaining re-entrant circuits is necessary and other anatomical structures are critical in this regard [Kottkamp et al. 2004; Pappone et al. 2001 ]. Several catheter-based strategies have been proposed and it seems reasonable that a predefined standardized approach, not based on consideration of the multifaceted nature of AF [Allessie et al. 1996], may not be equally effective in all patients. However, for AF to become sustained, the presence of an atrial substrate of sufficient mass capable of maintaining re-entrant circuits is necessary. The left atrium-PV junction and the posterior wall of left atrium are critical structures to this regard. Additionally, the vagal input to the atrium arises from several focal collections of nerves called ganglionic plexi, which happen to sit very near the openings of the pulmonary veins. There is some evidence that the effectiveness of the left atrial ablations depends largely on the ablation of these ganglia [Pappone et al. 2004] , especially in patients with paroxysmal AF.
Isolating or encircling all accessible PVs is identified as the cornerstone of any ablation approach [Natale et al. 2007; Jais et al. 2005] , indeed most of the trials used PV isolation as an endpoint for radiofrequency ablation. This approach, called 'empirical PV isolation', targets all of the PVs without regard to the initiation of ectopic beats ( Figure 1A and Figure 2 ). Multipolar circular catheters and basket catheters have been developed to facilitate identification of the electrical connections that are present at the junction of the atrium and the PV, and radiofrequency energy is applied in a circumferential fashion until PV entrance block is achieved. Successful isolation of the PV is verified by the disappearance of all PV potentials distal to the ablation site or the dissociation of the PV potentials relative to sinus rhythm. However, there were differences in the overall ablation strategy, including the approach to PV isolation and adjunctive ablation strategies (linear lines, complex fractionated electrogram ablation, etc.). Substrate modification Figure 2 . Non fluoroscopic-guided mapping and isolation of PV vestibula with the Nav-X mapping system (Endocardial Solution, Inc., USA). A 3D anatomic reconstruction of the left atrium is shown in postero-anterior view. can be achieved by additional linear lesions [Gaita et al. 2008] (Figure 1B) but the optimal lesion set to be deployed has yet to be elucidated. Additionally, it is uncertain whether all patients need further substrate modification to be cured of AF. Elimination of complex fractionated, atrial electrograms (CFAE) is another possible approach ( Figure 1C ). There is a growing body of evidence that such areas are ideal target sites for ablations to eliminate AF and maintain sinus rhythm [Ha|ssaguerre et al. 2005; Nademanee et al. 2004] . In a large proportion of patients, Oral et al. [2007] showed that ablation of CFAE is not sufficient to eliminate the driving mechanisms of chronic AF suggesting the routine isolation of all PVs. In addition Verma et al. [2007] reported in a retrospective study that the hybrid approach might be useful in patients with persistent/permanent AF. Recently, new software algorithms have been developed to improve CFAE detection [Calò et al. 2008; Scherr et al. 2007] ; however, the incremental benefit of this software over visual inspection remains to be established.
Controversies exist with regard to the procedural safety of AF ablation. Reports from single, high-volume, highly skilled centers claim very low complication rates. However recent surveys showed that this procedure is associated with approximately 5% risk of major complications [Bertaglia et al. 2007; Cappato et al. 2005] . Pulmonary vein stenosis, pericardial effusion, embolic cerebral complications and peripheral vascular complications constitute the most frequent complications. Continuing advances in this field might reduce the rate of major complications, additionally the increasing number of PV ablation procedures has allowed electrophysiologists to become aware of the peculiarities and potential dangers of these procedures. Additionally useful tools are required in order to plan the ablation strategy and to avoid more complex procedures with longer procedural durations and higher periprocedural risks. Phasedarray intracardiac echocardiography has been shown to be helpful in minimizing complications associated with ablation procedures by allowing real-time monitoring of both PV ostium and radiofrequency energy delivery [Marrouche et al. 2003 ].
Since the vast improvement in results, catheter ablation of AF is now a realistic therapeutic option across a broad spectrum of patients from patients with paroxysmal AF to those with longlasting persistent AF. The recent American Heart Association/American College of Cardiology/ European Society of Cardiology guidelines reflect this increasing volume of data and propose catheter ablation as a therapeutic option in AF management.
Conclusions
Atrial fibrillation is an independent predictor of all-cause mortality, irrespective of age, cardiac conditions or other comorbidities for reasons that remain poorly understood. Physicians have to determine strategies most appropriate for particular clinical conditions. Restoration and maintenance of sinus rhythm should reduce the likelihood of adverse events. Currently the mainstay of managing AF is drug therapy; however, in some patients not only is efficacy lower than desired, but prediction of antiarrhythmic versus arrhythmogenic effects of AADs in a particular case is nearly impossible. Consequently the limited efficacy and proarrhythmic risks of antiarrhythmic drug therapies for atrial fibrillation have led to the development of nonpharmacologic therapeutic approaches.
This decade has witnessed an increasing role in nonpharmacologic approaches such as catheter ablation in the treatment of highly symptomatic patients with atrial fibrillation that is refractory to drug therapy. Unlike electrical cardioversion or antiarrhythmic drugs, AF ablation offers the possibility of curing AF. Nevertheless, many aspects of the therapy are still controversial. Even though the results of published studies favor ablation therapy, large, well-designed, multicenter clinical trials are needed to confirm the efficacy and safety of this approach.
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